In a recent interview, Fran Gregory from Cardinal Health discussed the rapidly evolving landscape of cell and gene therapies (CGTs). She emphasized the significant progress made since the first CGT launch eight years ago, with projections suggesting that over 100,000 patients could benefit from these therapies by 2030. However, this growth comes with a projected financial burden of $75-$80 billion on the healthcare system, underscoring the need for innovative payment models and robust outcomes tracking. While the pipeline is primarily focused on oncology and hematology, there’s exciting diversification into areas like neurology and ophthalmology. Gregory stressed the importance of collaboration among stakeholders to enhance patient access and affordability, ensuring these transformative therapies fulfill their potential.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.pharmexec.com/view/asembia-2025-therapy-advancements-highlight-growing-cost-access-concerns
